Key result
Autophagy modulators fail to affect HRV2 synthesis, indicating viral multiplication is independent of autophagy.
Why the study?
The role of autophagy in the replication of human rhinovirus type 2 (HRV2) was unclear, despite evidence in related picornaviruses like poliovirus.
Does the induction or inhibition of autophagy affect human rhinovirus type 2 production?
Population
In vitro model of human rhinovirus type 2 infection
Comparison
Autophagy stimulators (tamoxifen, rapamycin) and inhibitor (3-methyladenine) vs control
Design
Preclinical experimental study
Authors
Loading...
HRV2 replication appears autophagy-independent in vitro; leaves open its dependence in other serotypes or in vivo models before any therapeutic consideration.
Does the induction or inhibition of autophagy affect human rhinovirus type 2 production?
Unlike poliovirus, the multiplication of human rhinovirus type 2 is not dependent on autophagic processes.
Brabec-Zaruba et al. (2007) studied Human rhinovirus type 2 (HRV2) infection. Tamoxifen, rapamycin, and 3-methyladenine (3-MA) was evaluated on De novo synthesis of human rhinovirus type 2 (HRV2). De novo synthesis of human rhinovirus type 2 (HRV2) is unaffected by autophagy-modulating drugs tamoxifen, rapamycin, and 3-methyladenine, indicating its multiplication is independent of autophagy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: